Overview

Aldara for the Treatment of Extensive Alopecia Areata

Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.
Phase:
Phase 4
Details
Lead Sponsor:
Hordinsky, Maria K., MD
Collaborators:
3M
National Alopecia Areata Foundation
Treatments:
Imiquimod